期刊
FRONTIERS IN NEUROLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2021.805135
关键词
cerebrospinal fluid; alpha-synuclein; skin biopsy; seeded aggregation assays; tau; amyloid; Lewy body dementia; LBDA biomarker symposium
The LBDA Biofluid/Tissue Biomarker Symposium, held by the Lewy Body Dementia Association, presented advancements in biomarkers for Lewy body dementia (LBD) and attracted over 200 scientists and physicians from various institutions. The methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology, as well as novel biomarkers, were discussed.
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health, and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology and novel biomarkers were discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据